Health Condition 1: N920- Excessive and frequent menstruation with regular cycle
Conditions
Interventions
Intervention1: Ormeloxifene: 3rd generation SERM (Selective Estrogen Receptor Modulator). Non steroidal Non Hormonal OCP.
Ormeloxifene will be given in the dose of 60mg twice a week for 3 months, fol
Sponsors
Nivedita Chawla
Eligibility
Inclusion criteria
Inclusion criteria: All perimenopausal females between the age of 39 to 51 years with abnormal uterine bleeding.
Exclusion criteria
Exclusion criteria: a. Pregnancy b. Organic Pelvic Pathology like polyp, fibroid, adenomyosis, endometriosis c. Systemic Pathology d. Coagulation disorders e. Breast malignancy f. Endometrial Hyperplasia with atypia g. Endocrine disorders like hypothyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the effectiveness of Ormeloxifene vs Medroxyprogesterone Acetate in cases of abnormal uterine bleeding in perimenopausal women.Timepoint: Follow up will be done at 2nd month, 4th month and 6th month | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢To study the effectiveness of Ormeloxifene in AUB in perimenopausal women. â?¢To study the effectiveness of Medroxyprogesterone Acetate in AUB in perimenopausal women. â?¢To compare Ormeloxifene versus Medroxyprogesterone Acetate in terms of PBAC Score, endometrial thickness by TVS, rise in haemoglobin and hematocrit AUB in perimenopausal women. At 2nd month symptomatic improvement, PBAC score and side effects will be assessed.Timepoint: 2nd, 4th and 6th month. | — |
Countries
India
Contacts
Public ContactDr Rehana Najam
Teerthanker Mahaveer Medical College
Outcome results
None listed